Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Alessandro Broccoli is active.

Publication


Featured researches published by Alessandro Broccoli.


Journal of Clinical Oncology | 2009

Role of [18F]Fluorodeoxyglucose Positron Emission Tomography Scan in the Follow-Up of Lymphoma

Pier Luigi Zinzani; Vittorio Stefoni; Monica Tani; Stefano Fanti; Gerardo Musuraca; Paolo Castellucci; Enrica Marchi; Mariapaola Fina; Valentina Ambrosini; Cinzia Pellegrini; Lapo Alinari; Enrico Derenzini; Giancarlo Montini; Alessandro Broccoli; Francesco Bacci; Stefano Pileri; Michele Baccarani

PURPOSE In lymphoma, [(18)F]fluorodeoxyglucose positron emission tomography (FDG-PET) is routinely used for initial staging, early evaluation of treatment response, and identification of disease relapse. However, there are no prospective studies investigating the value of serial FDG-PET over time in patients in complete remission. PATIENTS AND METHODS All patients with lymphoma who achieved the first complete remission were prospectively enrolled onto the study and scheduled for serial FDG-PET scans at 6, 12, 18, and 24 months; further scans were then carried out on an annual basis. Overall, the population included 421 patients (160 patients with Hodgkins lymphoma [HL], 183 patients with aggressive non-Hodgkins lymphoma [NHL], and 78 patients with indolent follicular NHL). All patients had a regular follow-up evaluation, including complete clinical and laboratory evaluation, and final assessment of any suspect FDG-PET findings using other imaging procedures (computed tomography [CT] scan) and/or biopsy and/or clinical evolution. FDG-PET findings were reported as positive for relapse, inconclusive (when equivocal), or negative for relapse. RESULTS PET enabled documentation of lymphoma relapse in 41 cases at 6 months, in 30 cases at 12 months, in 26 cases at 18 months, in 10 cases at 24 months, and in 11 cases at more than 36 months. All 36 patients with inconclusive positive PET underwent biopsy; only 12 (33%) of 36 patients had a concomitant suggestion of positivity on CT. A lymphoma relapse was diagnosed in 24 (66%) of 36 patients. CONCLUSION Our results confirm FDG-PET as a valid tool for follow-up of patients with HL and NHL. In patients with inconclusive positive results, histologic confirmation plays an important role in identifying true relapse.


Annals of Oncology | 2010

Gemcitabine as single agent in pretreated T-cell lymphoma patients: evaluation of the long-term outcome

Pier Luigi Zinzani; Filippo Venturini; Vittorio Stefoni; Mariapaola Fina; Cinzia Pellegrini; Enrico Derenzini; Letizia Gandolfi; Alessandro Broccoli; Lisa Argnani; Federica Quirini; Stefano Pileri; Michele Baccarani

BACKGROUND Peripheral T-cell lymphoma unspecified (PTCLU) and mycosis fungoides (MF) often show resistance to conventional chemotherapy. Gemcitabine should be considered a suitable option. We report the long-term update of 39 pretreated T-cell lymphoma patients treated with gemcitabine. PATIENTS AND METHODS From May 1997 to September 2007, 39 pretreated MF and PTCLU patients received gemcitabine. Inclusion criteria were as follows: histologic diagnosis of MF or PTCLU; relapsed/refractory disease; age > or =18 years; and World Health Organization performance status of two or less. Nineteen patients had MF and 20 PTCLU. All patients with MF had a T3-T4, N0, and M0 disease and patients with PTCLU had stage III-IV disease. Gemcitabine was given on days 1, 8, and 15 on a 28-day schedule (1200 mg/m(2)/day) for a total of three to six cycles. RESULTS Overall response rate was 51% (20 of 39 patients); complete response (CR) and partial response (PR) rates were 23% (9 of 39 patients) and 28% (11 of 39 patients), respectively. Patients with MF had a CR rate of 16% and a PR rate of 32% compared with a CR rate of 30% and a PR rate of 25% of PTCLU patients. Among the CR patients, 7 of 9 are in continuous complete response with a variable disease-free interval (15-120 months). CONCLUSION In our experience, gemcitabine proved to be effective in pretreated MF and PTCLU patients, even in the long term.


Clinical Lymphoma, Myeloma & Leukemia | 2011

Combination of Lenalidomide and Rituximab in Elderly Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma: A Phase 2 Trial

Pier Luigi Zinzani; Cinzia Pellegrini; Letizia Gandolfi; Vittorio Stefoni; Federica Quirini; Enrico Derenzini; Alessandro Broccoli; Lisa Argnani; Stefano Pileri; Michele Baccarani

BACKGROUND Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of aggressive non-Hodgkin lymphoma and despite recent chemotherapeutic advances up to half of all patients relapse. Here we report the results from a phase 2, single-arm, single-center trial evaluating the safety and efficacy of lenalidomide plus rituximab in elderly patients with relapsed or refractory DLBCL. PATIENTS AND METHODS Between March and June 2009, elderly patients (65 years of age or older) with relapsed/refractory DLBCL who had been heavily pretreated were recruited. Oral lenalidomide (20 mg/d for 21 days of each 28-day cycle) was initiated for four cycles and rituximab (375 mg/m(2)) was administered on day 1 and day 21 of each 28-day cycle for four cycles. After this induction phase, patients achieving a complete response (CR), partial response (PR), or stable disease (SD) were given lenalidomide maintenance therapy at the same schedule for another 8 months. RESULTS A total of 23 patients with a median of three prior treatments (range, 2 to 8) were included. The overall response rate (CR + PR) at the end of the induction phase was 35% (n = 8). Ten patients (7 CR, 1 PR, and 2 SD patients) were eligible for lenalidomide maintenance and 8 of these patients achieved a CR. Adverse events were manageable and the most common included neutropenia and thrombocytopenia. CONCLUSION Oral lenalidomide in combination with rituximab is active in elderly patients with relapsed/refractory DLBCL with a high percentage of patients achieving a continuous CR after lenalidomide maintenance.


The New England Journal of Medicine | 2015

Targeting Mutant BRAF in Relapsed or Refractory Hairy-Cell Leukemia

Enrico Tiacci; Jae H. Park; Luca De Carolis; Stephen S. Chung; Alessandro Broccoli; Sasinya N. Scott; Francesco Zaja; Sean M. Devlin; Alessandro Pulsoni; Young Rock Chung; Michele Cimminiello; Eunhee Kim; Davide Rossi; Richard Stone; Giovanna Motta; Alan Saven; Marzia Varettoni; Jessica K. Altman; Antonella Anastasia; Michael R. Grever; Achille Ambrosetti; Kanti R. Rai; Vincenzo Fraticelli; Mario E. Lacouture; Angelo Michele Carella; Ross L. Levine; Pietro Leoni; Alessandro Rambaldi; Franca Falzetti; Stefano Ascani

BACKGROUND BRAF V600E is the genetic lesion underlying hairy-cell leukemia. We assessed the safety and activity of the oral BRAF inhibitor vemurafenib in patients with hairy-cell leukemia that had relapsed after treatment with a purine analogue or who had disease that was refractory to purine analogues. METHODS We conducted two phase 2, single-group, multicenter studies of vemurafenib (at a dose of 960 mg twice daily)--one in Italy and one in the United States. The therapy was administered for a median of 16 weeks in the Italian study and 18 weeks in the U.S. study. Primary end points were the complete response rate (in the Italian trial) and the overall response rate (in the U.S. trial). Enrollment was completed (28 patients) in the Italian trial in April 2013 and is still open (26 of 36 planned patients) in the U.S. trial. RESULTS The overall response rates were 96% (25 of 26 patients who could be evaluated) after a median of 8 weeks in the Italian study and 100% (24 of 24) after a median of 12 weeks in the U.S. study. The rates of complete response were 35% (9 of 26 patients) and 42% (10 of 24) in the two trials, respectively. In the Italian trial, after a median follow-up of 23 months, the median relapse-free survival was 19 months among patients with a complete response and 6 months among those with a partial response; the median treatment-free survival was 25 months and 18 months, respectively. In the U.S. trial, at 1 year, the progression-free survival rate was 73% and the overall survival rate was 91%. Drug-related adverse events were usually of grade 1 or 2, and the events most frequently leading to dose reductions were rash and arthralgia or arthritis. Secondary cutaneous tumors (treated with simple excision) developed in 7 of 50 patients. The frequent persistence of phosphorylated ERK-positive leukemic cells in bone marrow at the end of treatment suggests bypass reactivation of MEK and ERK as a resistance mechanism. CONCLUSIONS A short oral course of vemurafenib was highly effective in patients with relapsed or refractory hairy-cell leukemia. (Funded by the Associazione Italiana per la Ricerca sul Cancro and others; EudraCT number, 2011-005487-13; ClinicalTrials.gov number NCT01711632.).


Cancer | 2011

Midtreatment 18F-fluorodeoxyglucose positron-emission tomography in aggressive non-Hodgkin lymphoma.

Pier Luigi Zinzani; Letizia Gandolfi; Alessandro Broccoli; Lisa Argnani; Stefano Fanti; Cinzia Pellegrini; Vittorio Stefoni; Enrico Derenzini; Federica Quirini; Michele Baccarani

The use of 18F‐fluorodeoxyglucose positron‐emission tomography (PET) scan has increased considerably in the clinical management of non‐Hodgkin lymphoma patients, and its role as a prognostic factor during chemotherapy has been established recently.


Clinical Cancer Research | 2010

Phase II Trial of Short-Course R-Chop Followed by 90Y-Ibritumomab Tiuxetan in Previously Untreated High-Risk Elderly Diffuse Large B-Cell Lymphoma Patients

Pier Luigi Zinzani; Giuseppe Rossi; Silvia Franceschetti; Barbara Botto; Alice Di Rocco; Maria Giuseppina Cabras; Maria Concetta Petti; Vittorio Stefoni; Alessandro Broccoli; Stefano Fanti; Cinzia Pellegrini; Gian Carlo Montini; Letizia Gandolfi; Enrico Derenzini; Lisa Argnani; Mariapaola Fina; Alessandra Tucci; Chiara Bottelli; Stefano Pileri; Michele Baccarani

Purpose: This study aimed to evaluate the efficacy and safety of the treatment with 90Y-ibritumomab tiuxetan following a short-course of rituximab with cyclophosphamide-adriamycin-vincristine-prednisone (R-CHOP) in high-risk elderly patients with previously untreated diffuse large B-cell lymphoma (DLBCL). Experimental Design: From December 2006 to October 2008, 55 high-risk elderly (age ≥60 years) untreated DLBCL patients were treated in seven Italian institutions with a short-course of chemotherapy consisting of four cycles of R-CHOP21 followed by 90Y-ibritumomab tiuxetan 6 to 10 weeks later. Results: Of the 55 patients, 48 underwent radioimmunotherapy. The overall response rate to the entire treatment regimen was 80%, including 73% complete remissions and 7% partial remissions. Eight (50%) of the 16 patients who achieved less than a complete response with CHOP improved their remission status after 90Y-ibritumomab tiuxetan administration. With a median follow-up of 18 months, the 2-year progression-free survival was estimated to be 85%, with a 2-year overall survival of 86%. 90Y-ibritumomab tiuxetan toxicity consisted of grade 3 to 4 hematologic toxicity in 28 of 48 patients, mainly neutropenia (23 patients) and thrombocytopenia (15 patients). Red cells and/or platelets transfusions were given to three patients. Conclusion: This study evaluated the feasibility, efficacy, and safety of a short-course R-CHOP21 regimen followed by 90Y-ibritumomab tiuxetan in high-risk elderly DLBCL patients. Clin Cancer Res; 16(15); 3998–4004. ©2010 AACR.


Clinical Lymphoma, Myeloma & Leukemia | 2009

Rituximab Combined With MACOP-B or VACOP-B and Radiation Therapy in Primary Mediastinal Large B-Cell Lymphoma: A Retrospective Study

Pier Luigi Zinzani; Vittorio Stefoni; Erica Finolezzi; Ercole Brusamolino; Maria Giuseppina Cabras; Annalisa Chiappella; Flavia Salvi; Andrea Rossi; Alessandro Broccoli; Maurizio Martelli

BACKGROUND Third-generation regimens (MACOP-B [methotrexate/leucovorin (LV)/doxorubicin/cyclophosphamide/vincristine/ prednisone/bleomycin] or VACOP-B [etoposide/LV/doxorubicin/cyclophosphamide/vincristine/prednisone/bleomycin]) in combination with local radiation therapy seem to improve lymphoma-free survival of primary mediastinal large B-cell lymphoma (PMLBCL). Recently, the superiority of R-CHOP (rituximab plus cyclophosphamide/doxorubicin/vincristine/ prednisone) over CHOP-like regimens has been demonstrated in elderly and younger patients with low-risk diffuse large B-cell lymphoma. PATIENTS AND METHODS Retrospectively, between February 2002 and July 2006, 45 previously untreated patients with PMLBCL were treated with a combination of a third-generation chemotherapy regimen (MACOP-B or VACOP-B), concurrent rituximab, and mediastinal radiation therapy. RESULTS Twenty-six (62%) patients achieved a complete response (CR), and 15 (36%) obtained a partial response after MACOP-B/VACOP-B plus rituximab. After radiation therapy, the CR rate was 80%. At a median follow-up of 28 months, among the 34 patients who obtained a CR, 3 relapsed after 16, 19, and 22 months, respectively. Projected overall survival was 80% at 5 years; the relapse-free survival (RFS) curve of the 34 patients who achieved CR was 88% at 5 years. CONCLUSION In this retrospective study, in patients with PMLBCL, combined-modality treatment using the MACOP-B/VACOP-B regimen plus rituximab induces a high remission rate, with patients having a > 80% chance of surviving relapse free at 5 years. In comparison with historical data on MACOP-B/VACOP-B without rituximab, there are no statistically significant differences in terms of CR and RFS rates.


Journal of Clinical Oncology | 2016

Interim Positron Emission Tomography Response-Adapted Therapy in Advanced-Stage Hodgkin Lymphoma: Final Results of the Phase II Part of the HD0801 Study.

Pier Luigi Zinzani; Alessandro Broccoli; Daniela Gioia; Antonio Castagnoli; Giovannino Ciccone; Andrea Evangelista; Armando Santoro; Umberto Ricardi; Maurizio Bonfichi; Ercole Brusamolino; Giuseppe Rossi; Antonella Anastasia; Francesco Zaja; Umberto Vitolo; Vincenzo Pavone; Alessandro Pulsoni; Luigi Rigacci; Gianluca Gaidano; Caterina Stelitano; Flavia Salvi; Chiara Rusconi; Monica Tani; Roberto Freilone; Patrizia Pregno; Eugenio Borsatti; Gian Mauro Sacchetti; Lisa Argnani; Alessandro Levis

PURPOSE The clinical impact of positron emission tomography (PET) evaluation performed early during first-line therapy in patients with advanced-stage Hodgkin lymphoma, in terms of providing a rationale to shift patients who respond poorly onto a more intensive regimen (PET response-adapted therapy), remains to be confirmed. PATIENTS AND METHODS The phase II part of the multicenter HD0801 study involved 519 patients with advanced-stage de novo Hodgkin lymphoma who received an initial treatment with doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) and who underwent an early ifosfamide-containing salvage treatment followed by stem-cell transplantation if they showed a positive PET evaluation after two cycles of chemotherapy (PET2). The primary end point was 2-year progression-free survival calculated for both PET2-negative patients (who completed a full six cycles of ABVD treatment) and PET2-positive patients. Overall survival was a secondary end point. RESULTS In all, 103 of the 512 evaluable patients were PET2 positive. Among them, 81 received the scheduled salvage regimen with transplantation, 15 remained on ABVD (physicians decision, mostly because of minimally positive PET2), five received an alternative treatment, and two were excluded because of diagnostic error. On intention-to-treat analysis, the 2-year progression-free survival was 76% for PET2-positive patients (regardless of the salvage treatment they received) and 81% for PET2-negative patients. CONCLUSION Patients with advanced-stage Hodgkin lymphoma for whom treatment was at high risk of failing appear to benefit from early treatment intensification with autologous transplantation, as indicated by the possibility of successful salvage treatment in more than 70% of PET2-positive patients through obtaining the same 2-year progression-free survival as the PET2-negative subgroup.


Leukemia & Lymphoma | 2011

Lenalidomide monotherapy for relapsed/refractory peripheral T-cell lymphoma not otherwise specified

Pier Luigi Zinzani; Cinzia Pellegrini; Alessandro Broccoli; Vittorio Stefoni; Letizia Gandolfi; Federica Quirini; Lisa Argnani; Emilio Berti; Enrico Derenzini; Stefano Pileri; Michele Baccarani

Current therapeutic strategies for peripheral T-cell lymphoma, not otherwise specified (PTCL-nos) remain poorly defined; they are extrapolated from treatment paradigms of B-cell lymphomas. In particular, patients with aggressive PTCL are traditionally treated with an anthracycline-containing regimen, and complete response rates of 50–70% have been reported [1–3]. However, 5-year overall survival (OS) for patients with PTCL-nos was 20–30%. Autologous stem cell transplant (ASCT) seems to offer long-term disease control in only 30–40% of cases if performed in a status of remission [4,5]. In recent years, there have been a plethora of new agents that have shown promising activity in the treatment of patients with PTCL. Pralatrexate, a new antifolate, showed an overall response rate (ORR) of 29%, with 9% of patients achieving complete remission (CR) in a prospective single-arm multicenter study [6] of relapsed/refractory PTCL. Among histone deacetylase inhibitors (HDACIs), a phase II trial of romidepsin in patients with PTCL who had failed at least one systemic therapy showed an ORR of 31% (with a CR rate of 8%) [7]. Gemcitabine, a nucleoside analogous, has been studied as a single agent in relapsed patients with PTCL, and showed an ORR of 59% with 12% CRs [8,9]. Lenalidomide is an immunomodulatory agent with potent anticancer properties. A phase II trial of lenalidomide in PTCL was reported by Dueck and co-workers [10] in which 24 patients with T-cell lymphoma were enrolled; the ORR was 30%, without CRs. On the strength of these findings we decided to investigate the efficacy and safety of lenalidomide monotherapy in pretreated patients with PTCL-nos. Patients aged 18 years or older with biopsy-proven, bidimensionally measurable, stage II, III or stage IV PTCL-nos were considered eligible for this prospective, single-arm, open-label, bi-centric non-randomized phase II trial. Patients were to be relapsed ( 1) or refractory and should have a World Health Organization (WHO) performance status 2. All diagnostic biopsies were reviewed by an expert pathologist (S.P.) in accordance with the WHO classification [11]. All the patients underwent full medical history, physical examination, complete blood cell and platelet counts, a computed tomography (CT) scan of the neck, chest, abdomen, and pelvis, whole-body F-fluorodeoxyglucose (FDG)-positron emission tomography (PET) scan, and a bone marrow biopsy. Disease stage was established according to the Ann Arbor staging system. Patients were also tested for kidney and liver function (including hepatitis B and C viruses [HBV and HCV]) and were subjected to electrocardiography. All patients signed a written informed consent, approved in accordance with institutional guidelines, including the Declaration of Helsinki. The study was approved by the institutional review board.


Annals of Oncology | 2010

MACOP-B regimen in the treatment of adult Langerhans cell histiocytosis: experience on seven patients

Enrico Derenzini; Mariapaola Fina; Vittorio Stefoni; Cinzia Pellegrini; Filippo Venturini; Alessandro Broccoli; Letizia Gandolfi; Stefano Pileri; Stefano Fanti; Egesta Lopci; Paolo Castellucci; Claudio Agostinelli; Michele Baccarani; Pier Luigi Zinzani

BACKGROUND Adult Langerhans cell histiocytosis (LCH) is a rare disease. The combination of vinblastine and prednisone, given in a 6-month course, is the standard of care but prospective randomized trials are lacking. PATIENTS AND METHODS We report our monocentric experience in the treatment of seven adult patients with multisystem (MS) LCH (n = 3) or single-system multifocal (SS-m) LCH (n = 4) with the short-course intensive chemotherapy regimen methotrexate, doxorubicin, cyclophosphamide, vincristine, prednisone and bleomicin (MACOP-B). RESULTS The overall response rate was 100% [five complete response (CR), two partial response (PR)]. After a median follow-up of 6.5 years, four patients are in first continuous CR and three patients relapsed after 5, 8 and 62 months, respectively. Four patients were evaluated with positron emission tomography (PET) scan: all three PET-negative patients at the end of treatment had a long-lasting response with only one patient relapsing after 5 years. PET scan detected additional bone lesions at diagnosis in two of four patients, changing the treatment program in one of them. CONCLUSIONS MACOP-B regimen seems to be very active in the treatment of adult MS or SS-m LCH, with long-lasting responses in five of seven patients. PET scan merits further evaluation in the initial staging and in the evaluation of the response to chemotherapy.

Collaboration


Dive into the Alessandro Broccoli's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge